Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Nihon Chouzai Co's average EBITDA Per Share Growth Rate was 200.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -4.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -6.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nihon Chouzai Co was 31.90% per year. The lowest was -5.80% per year. And the median was 7.15% per year.
Nihon Chouzai Co (OTCPK:NHCZF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nihon Chouzai Co 3-Year EBITDA Growth Rate Related Terms
Nihon Chouzai Co 3-Year EBITDA Growth Rate Competitor Comparison
For the Pharmaceutical Retailers subindustry, Nihon Chouzai Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nihon Chouzai Co 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nihon Chouzai Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nihon Chouzai Co's 3-Year EBITDA Growth Rate falls into.
Nihon Chouzai Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -4.60% mean?
Nihon Chouzai Co (NHCZF) has a 3-Year EBITDA Growth Rate of -4.60% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nihon Chouzai Co and its competitors.
Is Nihon Chouzai Co's 3-Year EBITDA Growth Rate too high?
Nihon Chouzai Co's current 3-Year EBITDA Growth Rate is -4.60%. Overall, Nihon Chouzai Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Nihon Chouzai Co's 3-Year EBITDA Growth Rate compare to competitors?
Nihon Chouzai Co's 3-Year EBITDA Growth Rate of -4.60% can be compared against companies in the Healthcare Providers & Services industry. The industry median 3-Year EBITDA Growth Rate is 10.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nihon Chouzai Co and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nihon Chouzai Co's current 3-Year EBITDA Growth Rate is -4.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nihon Chouzai Co stock overvalued right now?
Nihon Chouzai Co (NHCZF) has a current 3-Year EBITDA Growth Rate of -4.60%. The stock's GF Value™ is $6.38, compared to a current price of $16.02 — trading 151.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -4.60%. Nihon Chouzai Co's overall GF Score™ is 9/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nihon Chouzai Co (NHCZF), the current 3-Year EBITDA Growth Rate is -4.60% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nihon Chouzai Co (NHCZF) Overvalued in 2026?
Based on GuruFocus' analysis, Nihon Chouzai Co stock appears to be overvalued.
The current stock price of $16.02 is trading 151.1% above its estimated GF Value™ of $6.38.
Key valuation signals for NHCZF:
3-Year EBITDA Growth Rate: -4.60%
GF Value™: $6.38 vs. price of $16.02 (151.1% above fair value)
No single metric tells the full story. See the NHCZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nihon Chouzai Co Ltd operates in the pharmaceutical industry. The company is organized into segments: Pharmacy, Pharmaceutical Manufacturing and Sales, and Healthcare Staffing Services and operates mainly from Japan. Through its operating segments, the firm manages a chain of pharmacies nationwide, manufactures and sells generic drugs, and provides staffing services that are specialized in pharmacy.
9GF Score
Get the complete analysis for NHCZF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NHCZF has been successfully added to your 
